Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances. Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances. Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable Circumstances Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Abstract: The present invention provides active cytokine and/or chemokine compositions, as well as inexpensive means for the production, amended-cell encasement of active cytokine and/or chemokine compositions, processing, and delivery of active cytokine and/or chemokine compositions. The subject invention also provides methods of treatment and methods of accelerating an immune response comprising the administration of amended recombinant cell (ARC) containing cytokine and/or chemokine compositions to animals or humans.

Abstract: The present invention provides active cytokine and/or chemokine compositions, as well as inexpensive means for the production, amended-cell encasement of active cytokine and/or chemokine compositions, processing, and delivery of active cytokine and/or chemokine compositions. The subject invention also provides methods of treatment and methods of accelerating an immune response comprising the administration of amended recombinant cell (ARC) containing cytokine and/or chemokine compositions to animals or humans.

Abstract: Two novel linear DNA plasmids are described. Also, novel fragments of the plasmids containing the autonomous replication sequence (ARS), and thus capable of self-maintenance as extra chromosomal elements are provided. These novel DNA sequences of the present invention are useful in a vector for self-maintenance in Pichia pastoris and are also useful as plasmid vectors which can be shuttled between yeast and bacteria.

Abstract: The invention concerns a novel isolate of Bacillus thuringiensis which has activity against protozoans. Thus, this isolate, designated PS81F, or the purified protein toxin, or inclusion bodies from this isolate, can be used to treat humans and animals hosting a parasitic protozoan. Further, the gene encoding the toxin can be transferred to a suitable host via a biological vector, e.g., a plasmid or virus.

Abstract: This invention concerns novel gene probes which can be used to identify DNA from Bacillus thuringiensis microbes which encode protein endotoxins. The invention probes greatly facilitate the search for useful microbes hosting genes which encode toxins.

Abstract: Novel biological pesticides are prepared by introducing into a microorganism the genetic capability to produce a heterologous pesticide, wherein the microorganism is capable of proliferating in the rhizosphere or phylloplane in competition with wild-type microorganisms. A gene capable of expressing a polypeptide is introduced into the microorganism under conditions which allow for stable maintenance and expression of the gene, without significantly diminishing the ability of the microorganism to compete in the environment. Preferred microorganisms provide for the maintenance and protection from degradation of the polypeptide pesticide.

Abstract: This invention concerns novel gene probes which can be used to identify DNA from Bacillus thuringiensis microbes which encode insecticidally-active protein endotoxins. The invention probes greatly facilitate the search for useful microbes hosting genes which encode insecticidally-active toxins.

Abstract: The subject invention concerns a novel and useful insecticide with activity against insect pests of the order Coleoptera and the order Lepidoptera. Pests in the order Coleoptera do heavy damage to crops, e.g., corn. The insecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. MT 104, or mutants thereof. The spores or crystals of this microbe are useful to control coleopteran and lepidopteran pests in various environments.